Sumitomo Pharma Co Ltd - Company Profile

Powered by

All the data and insights you need on Sumitomo Pharma Co Ltd in one report.

  • Save hours of research time and resources with
    our up-to-date Sumitomo Pharma Co Ltd Strategy Report

  • Understand Sumitomo Pharma Co Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Sumitomo Pharma Co Ltd: Overview

Sumitomo Pharma Co Ltd (Sumitomo Pharma), formerly Sumitomo Dainippon Pharma Co Ltd, develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. The company offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Pharma has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Chuo-ku, Osaka, Japan.

Gain a 360-degree view of Sumitomo Pharma Co Ltd and make more informed decisions for your business Gain a 360-degree view of Sumitomo Pharma Co Ltd and make more informed decisions for your business Find out more
Headquarters Japan

Address 2-6-8, Dosho-Machi, Chuo-Ku, Osaka-Shi, 541-0045


Telephone 81 6 62035321

No of Employees 6,250

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 4506 (TYO)

Revenue (2022) $4.1B -0.8% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ -232.1% (2022 vs 2021)

Market Cap* $1.1B

Net Profit Margin (2022) XYZ -233.2% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Sumitomo Pharma Co Ltd premium industry data and analytics

560+

Clinical Trials

Determine Sumitomo Pharma Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

330+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Sumitomo Pharma Co Ltd’s relevant decision makers and contact details.

320+

Catalyst Calendar

Proactively evaluate Sumitomo Pharma Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

180+

Pipeline Drugs

Identify which of Sumitomo Pharma Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

90+

Marketed Drugs

Understand Sumitomo Pharma Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

40+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Sumitomo Pharma Co Ltd and assess market opportunity for new entrants with patient population 8-year forecasts.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

30+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Sumitomo Pharma Co Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pharmaceuticals: Gemtesa
Oncology Drugs Latuda
Psychiatry and Neurology Drugs Equa
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Sumitomo Pharma Co Ltd portfolio and identify potential areas for collaboration Understand Sumitomo Pharma Co Ltd portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In November, Sumitomo Pharmaceuticals (Suzhou) Co. secured approval from the National Drug Administration of China for XENLETA to treat patients with community-acquired pneumonia in adults.
2023 Contracts/Agreements In September, the company entered into a research collaboration with Salipro Biotech to reveal the mechanism of action and pharmacological characterization of a drug candidate.
2023 Plans/Strategy In September, the company announced its plans to change the name of Myovant Sciences GmbH to Sumitomo Pharma Switzerland GmbH.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Sumitomo Pharma Co Ltd Takeda Pharmaceutical Co Ltd Astellas Pharma Inc Daiichi Sankyo Co Ltd Chugai Pharmaceutical Co Ltd
Headquarters Japan Japan Japan Japan Japan
City Osaka-Shi Chuo-Ku Chuo-Ku Chuo-Ku Chuo-Ku
State/Province Osaka Tokyo Tokyo Tokyo Tokyo
No. of Employees 6,250 49,095 14,484 17,435 7,771
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Masayo Tada Chairman Executive Board - -
Hiroshi Nomura Director; Chief Executive Officer; President Executive Board 2018 -
Toru Kimura Executive Vice President; Chief Scientific Officer - Regenerative & Cellular Medicine Office; Regenerative and Cellular Medicine Kobe Center; Regenerative and Cellular Medicine Manufacturing Plant; Director Executive Board 2021 -
Shigeyuki Nishinaka Senior Executive Officer-Business Development & Management; Director Executive Board 2022 -
Koji Ishida Chairman - Sumitomo Dainippon Pharma America, Inc; Chief Executive Officer - Sumitomo Dainippon Pharma America, Inc Executive Board 2021 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Sumitomo Pharma Co Ltd key executives to enhance your sales strategy Gain insight into Sumitomo Pharma Co Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward